1525 related articles for article (PubMed ID: 11221829)
1. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment.
Adamsen BL; Kravik KL; Clausen OP; De Angelis PM
Int J Oncol; 2007 Dec; 31(6):1491-500. PubMed ID: 17982676
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
Muneoka K; Shirai Y; Yokoyama N; Wakai T; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Feb; 32(2):231-3. PubMed ID: 15751639
[TBL] [Abstract][Full Text] [Related]
5. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Kusunoki M; Yanagi H; Noda M; Yoshikawa R; Yamamura T
Cancer; 2000 Sep; 89(6):1228-35. PubMed ID: 11002217
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
7. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Matsui SI; Arredondo MA; Wrzosek C; Rustum YM
Cancer Res; 1996 Oct; 56(20):4715-23. PubMed ID: 8840989
[TBL] [Abstract][Full Text] [Related]
8. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
9. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M
Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597
[TBL] [Abstract][Full Text] [Related]
10. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
Muneoka K; Shirai Y; Wakai T; Yokoyama N; Okumura S; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):799-802. PubMed ID: 15984519
[TBL] [Abstract][Full Text] [Related]
12. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
Suzuka I; Izumi S; Onoda Y; Shiota K; Nishihara M; Nakagawa J; Shimizu N
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2183-8. PubMed ID: 10635302
[TBL] [Abstract][Full Text] [Related]
15. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
[TBL] [Abstract][Full Text] [Related]
16. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
17. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
[TBL] [Abstract][Full Text] [Related]
18. [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
Yokoo H; Kamiyama T; Nakagawa T; Nakanishi K; Tahara M; Fukumori D; Kamachi H; Matsushita M; Todo S
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2400-3. PubMed ID: 20037436
[TBL] [Abstract][Full Text] [Related]
19. [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
Maruyama S; Maruyama M; Kato K; Koide A; Ohbu M; Hasegawa K; Takashima I; Ebuchi M
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1743-5. PubMed ID: 15553701
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
